Frontiers in Immunology (Jul 2024)

Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2

  • Juan Liu,
  • Huafeng Han,
  • Binbin Yang,
  • Naifang Zhang,
  • Jing Li,
  • Xicheng Chen,
  • Jie Wu,
  • Yingying Zhao,
  • Yongsheng Yang

DOI
https://doi.org/10.3389/fimmu.2024.1416375
Journal volume & issue
Vol. 15

Abstract

Read online

With the rapid global spread of COVID-19 and the continuous emergence of variants, there is an urgent need to develop safe and effective vaccines. Here, we developed a novel mRNA vaccine, HC009, based on new formulation by the QTsome delivery platform. Immunogenicity results showed that the prime-boost immunization strategy with HC009 was able to induce robust and durable humoral immunity, as well as Th1-biased cellular responses in rodents or non-human primates (NHPs). After further challenge with live SARS-CoV-2 virus, HC009 provided adequate protection against virus infection in hACE2 transgenic mice. Therefore, HC009 could provide significant immune protection against SARS-CoV-2.

Keywords